Molecular and Cellular Biochemistry

, Volume 145, Issue 1, pp 61–68 | Cite as

The proteoglycan perlecan is expressed in the erythroleukemia cell line K562 and is upregulated by sodium butyrate and phorbol ester

  • Susanne Grässel
  • Isabelle R. Cohen
  • Alan D. Murdoch
  • Inge Eichstetter
  • Renato V. Iozzo
Article
Received:
Accepted:

Abstract

Perlecan is a modular heparan sulfate proteoglycan that harbors five domains with homology to the low density lipoprotein receptor, epidermal growth factor, laminin and neural cell adhesion molecule. Using a monoclonal antibody directed against the laminin-like domain of perlecan, we have recently shown that perlecan is widely expressed in all lymphoreticular systems. To investigate further this observation we have studied the expression of perlecan in two human leukemic cell lines. Using reverse transcriptase-PCR, ribonuclease protection assay, and metabolic labeling we detected significant perlecan expression in the multipotential cell line K562, originally derived from a patient with chronic myelogenous leukemia. In contrast, the promyelocytic cell line HL-60 expressed perlecan at barely detectable levels. These results were intriguing because the K562 cells do not assemble or produce a classical basement membrane. Following induction with either sodium butyrate or the phorbol diester 12-0-tetradecanoylphorbol-13-acetate (TPA), K562 and HL-60 differentiate into early progenitor cells with erythroid or megakaryocytic properties, respectively. Following treatment of K562 and HL-60 cells with either of these agents, perlecan expression was markedly increased in K562 cells. In contrast, we could detect perlecan protein synthesis in HL-60 cells only at very low levels, even after induction with TPA or sodium butyrate. Collectively, these results indicate that perlecan is actively synthesized by bone marrow derived cells and suggest that this proteoglycan may play a role in hematopoietic cell differentiation.

Key Words

perlecan proteoglycan heparan sulfate K562 HL-60 TPA sodium butyrate 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Iozzo RV: Perlecan: A gem of a proteoglycan. Matrix Biol 14: 203–208, 1994Google Scholar
  2. 2.
    Iozzo RV, Cohen IR, Grässel S, Murdoch AD: The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302: 625–639, 1994Google Scholar
  3. 3.
    Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV: Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42: 239–249, 1994Google Scholar
  4. 4.
    Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321–334, 1975Google Scholar
  5. 5.
    Jokinen M, Gahmberg CG, Andersson L Biosynthesis of the major human red cell sialoglycoprotein, glycophorin A, in a continuous cell line. Nature 279: 604–607, 1979Google Scholar
  6. 6.
    Andersson LC, Jokinen M, Gahmberg CG: Induction of erythroid differentiation in the human leukaemia cell line K562. Nature 278: 364–365, 1979Google Scholar
  7. 7.
    Rutherford TR, Clegg JB, Weatherall DJ: K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. Nature 280: 164–165, 1979Google Scholar
  8. 8.
    Andersson LC, Nilsson K, Gahmberg CG: K562—A human erythroleukemic cell line. Int J Cancer 23: 143–147, 1979Google Scholar
  9. 9.
    Siebert PD, Fukuda M: Regulation of glycophorin gene expression by a tumor-promoting phorbol ester in human leukemic K562 cells. J Biol Chem 260: 640–645, 1985Google Scholar
  10. 10.
    Lorkowsky G, Zijderhand-Bleekemolen JE, Erdös EG, von Figura K, Hasilik A: Neutral endopeptidase−24.11 (enkephalinase): biosynthesis and localization in human fibroblasts. Biochem J 248: 345–350, 1987Google Scholar
  11. 11.
    Whitehead TP, Kricka LJ, Carter TJN, Thorpe GHG: Analytical luminescence: its potential in the clinical laboratory. Clin Chem 25: 1531–1546, 1979Google Scholar
  12. 12.
    Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold-Spring Harbor, NY, 1989Google Scholar
  13. 13.
    Yamagata T, Saito H, Habuchi O, Suzuki S: Purification and properties of bacterial chondroitinases and chondrosulfatases. J Biol Chem 243: 1523–1535, 1968Google Scholar
  14. 14.
    Linker A, Hovingh P: Heparinase and heparitinase from Flavobacteria. Methods Enzymol 28: 902–911, 1972Google Scholar
  15. 15.
    Thornton DJ, Nieduszynski IA, Oates K, Sheehan JK: Electronmicroscopic and electrophoretic studies of bovine femoral-head cartilage proteoglycan fractions. Biochem J 240: 41–48, 1986Google Scholar
  16. 16.
    Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV: Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/Perlecan). J Biol Chem 267: 8544–8557, 1992Google Scholar
  17. 17.
    Iozzo RV: Biosynthesis of heparan sulfate proteoglycan by human colon carcinoma cells and its localization at the cell surface. J Cell Biol 99: 403–417, 1984Google Scholar
  18. 18.
    Lozzio BB, Lozzio CB, Bamberger EG, Feliu AS: A multipotential leukemia cell line (K562) of human origin (41106). Proc Soc Exp Biol Med 166: 546–550, 1981Google Scholar
  19. 19.
    Isemura M, Sato N, Yamaguchi Y, Aikawa J, Munakata H, Hayashi N, Yosizawa Z, Nakamura T, Kubota A, Arakawa M, Hsu CC: Isolation and characterization of fibronectin-binding proteoglycans carrying both heparan sulfate and dermatan sulfate chains from human placenta. J Biol Chem 262: 8926–8933, 1987Google Scholar
  20. 20.
    Danielson KG, Martinez-Hernandez A, Hassell JR, Iozzo RV: Establishment of a cell line from the EHS tumor: Biosynthesis of basement membrane constituents and characterization of a hybrid proteoglycan containing heparan and chondroitin sulfate chains. Matrix 11: 22–35, 1992Google Scholar
  21. 21.
    Noonan DM, Fulle A, Valente P, Cai S, Horigan E, Sasaki M, Yamada Y, Hassell JR: The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266: 22939–22947, 1991Google Scholar
  22. 22.
    Rogalski TM, Williams BD, Mullen GP, Moerman DG: The products of the unc-52 gene inCaenorhabditis elegans are homologous to the core protein of the mammalian basement membrane heparan sulfate proteoglycan. Genes Dev 7: 1471–1481, 1993Google Scholar
  23. 23.
    Cohen IR, Grässel S, Murdoch AD, Iozzo RV: Structural characterization of the complete human perlecan gene and its promoter. Proc Natl Acad Sci USA 90: 10404–10408, 1993Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Susanne Grässel
    • 1
  • Isabelle R. Cohen
    • 1
  • Alan D. Murdoch
    • 1
  • Inge Eichstetter
    • 1
  • Renato V. Iozzo
    • 1
  1. 1.Department of Pathology and Cell Biology and the Jefferson Cancer InstituteThomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations